But I don’t feel that we need to do anything like that to cover a top-line gap. If we ever did something like that, it was because it would be strategic and looking at the Company long term and not trying to fill a top-line gap.
Mike Comilla: Operator, I’ll take one more question, please.
Operator: Thank you. And our last question will come from Travis Steed from B of A Securities. Your line is open.
Travis Steed: Hi, everybody. Thanks for taking the question. So some of the insurance companies are getting surprised by higher procedure utilization, some of the companies are kind of calling out above normal growth. So I’m curious, Robert, if you look at your med device markets, are there areas where you think you’re seeing some kind of above elevated catch-up still coming through? Or do you think this is kind of more normalized growth rates that you’re seeing in 2024? I’m just kind of curious on some of your thoughts on the overall market.
Robert Ford: Yes, I don’t think that we’re seeing kind of any kind of catch-up or pent-up or anything like that. I think what you’re seeing here is more, at least I can speak for our portfolio, I just think you’re seeing more adoption of the technologies, right? So I think there was some disruption. We’ve talked about it in some parts of some procedures that require a little bit more pre-op planning or imaging before and imaging after. I think that combined with the labour shortages that occurred 2022, I think that that probably slowed a few of them down. But I don’t think that there was a bolus returning as a result of that. I just think we got back into a normal cadence here of being able to see procedures increasing. We saw that in structural heart procedures, saw that in CRM and NDP procedures, not just here in the U.S., but around the world too.
So seeing that also in routine diagnostic testing, Travis, a good portion of our diagnostic business, our core lab business, is actually in the hospital. So we also get to see that too. And I didn’t see a bolus of testing coming back. So we try and triangulate this. I just see this as procedures are returning back to normal and because these technologies that are being developed and launched to the market are so, it got such great opportunity to improve care, improve life of patients. I just think you’re seeing the return to the adoption and the adoption curve. Some are faster than others, just given, I think, the market and market positions, et cetera. But I wouldn’t account for it to be some sort of pent up piece over here. Okay. Well, I’ll wrap up here.
And like I said in the beginning, very successful year 2023 in many ways, it’s sort of represented this transition year regarding the coming down of COVID. I think we did a really good job at managing the scale up and the scale down. A lot of healthcare companies actually participated in trying to solve the COVID problem. And I think we did a good job here at being able to scale up and scale down. Our performance here is now transitioned from being driven by COVID testing to once again, being driven by a broad-based strength across the entire Company. We deliver double digit organic sales growth on every base business on every quarter. And we’re clearly entering 2024 with a lot of momentum. The pipeline, we talked a bit about it, continues to be highly productive.
And I’m forecasting here, top-tier growth in 2024. And as you look at our range on the EPS guide, like I said, there’s probably more upside to that than downside, but we’re in January. So we’re off to a good start and looking forward to executing this year.
Mike Comilla: Okay. Thank you, operator. And thank you all for your questions. This now concludes Abbott’s conference call. A webcast replay of this call will be available after 11 a.m. Central time today on Abbott Investor Relations website at abbottinvestor.com. Thank you for joining us today.
Operator: Thank you. This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.
